By Fineline Cube 
Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ), a subsidiary of Sino Biopharmaceutical Ltd (HKG: 1177), announced that China’s National Medical Products Administration (NMPA) has granted priority review designation for a market filing of LM-302, an antibody-drug conjugate (ADC) developed by its subsidiary LaNova Medicines Ltd, for the treatment of CLDN18.2-positive, locally advanced or metastatic gastric/gastroesophageal junction adenocarcinoma in patients who have received at least two prior systemic therapies.
Regulatory Status & Corporate Structure
| Parameter | Detail |
|---|---|
| Filing Company | Jiangsu Chia Tai Tianqing Pharmaceutical Co., Ltd. (CTTQ) |
| Parent Company | Sino Biopharmaceutical Ltd (HKG: 1177) |
| Developer | LaNova Medicines Ltd (subsidiary) |
| Regulatory Agency | National Medical Products Administration (NMPA), China |
| Review Status | Priority review granted |
| Indication | CLDN18.2-positive gastric/GEJ adenocarcinoma (≥2 prior systemic therapies) |
| Drug Class | CLDN18.2-targeting antibody-drug conjugate (ADC) |
Molecular Profile & Mechanism of Action
ADC Structure
- Antibody Component: Recombinant humanized monoclonal antibody targeting CLDN18.2
- Payload: Monomethyl auristatin E (MMAE) – potent cytotoxic small-molecule toxin
- Target Antigen: CLDN18.2 (Claudin 18.2) – highly expressed in gastric cancers
Unique Therapeutic Advantages
- Precision Targeting: Selective binding to CLDN18.2-positive tumor cells
- Bystander Effect: Eliminates surrounding heterogeneous tumor cells lacking target expression
- Immunogenic Cell Death (ICD): Induces tumor antigen release and immune activation
- Combination Synergy: Demonstrates significant synergistic antitumor effect with anti-PD-1 antibodies
Complex Corporate History & Strategic Evolution
Licensing & Acquisition Timeline
- May 2022: LaNova out-licensed LM-302 to Turning Point Therapeutics (TPTX.US) for $25M upfront + up to $1B milestones (ex-China/South Korea rights)
- June 2022: Bristol Myers Squibb (BMS) acquired Turning Point, inheriting LM-302 alongside repotrectinib
- October 2024: BMS returned LM-302 rights to LaNova
- July 2025: Sino Biopharmaceutical acquired LaNova, integrating LM-302 into CTTQ’s development pipeline
This complex transaction history reflects the evolving strategic value of CLDN18.2-targeting therapies and Sino Biopharmaceutical’s commitment to building a world-class oncology portfolio through its CTTQ subsidiary.
Market Opportunity & Clinical Significance
Gastric cancer represents a major health burden in China, with approximately 450,000 new cases annually and poor survival rates in advanced stages. The CLDN18.2 biomarker is expressed in 30-40% of gastric adenocarcinomas, creating a substantial addressable patient population.
The “ADC + immunotherapy” combination strategy positions LM-302 as a potential backbone therapy for deeper and more durable tumor responses. With limited effective options available for third-line gastric cancer treatment, LM-302 addresses a critical unmet medical need.
Priority review designation suggests the NMPA recognizes the clinical urgency and potential benefit of this novel therapeutic approach, potentially accelerating approval timeline by several months compared to standard review.
Competitive Landscape
LM-302 competes in the emerging CLDN18.2-targeted therapy space, where several companies are developing monoclonal antibodies and ADCs. However, LM-302’s dual mechanism combining direct cytotoxicity with immunogenic cell death may provide differentiation in efficacy and durability of response.
Jiangsu Chia Tai Tianqing’s established commercial infrastructure and Sino Biopharmaceutical’s integrated development capabilities position the company well to rapidly deploy LM-302 upon approval and potentially expand into earlier lines of therapy through combination studies.
Forward-Looking Statements
This brief contains forward-looking statements regarding regulatory approvals, clinical development, and commercial expectations. Actual results may differ due to risks including final regulatory decisions, clinical trial outcomes, competitive dynamics, and market access negotiations.-Fineline Info & Tech